GCG100649, A Novel Cyclooxygenase-2 Inhibitor, Exhibits a Drug Disposition Profile in Healthy Volunteers Compatible With High Affinity to Carbonic Anhydrase-I/II: Preliminary Dose-Exposure Relationships to Define Clinical Development Strategies-Reference-Cited by-同舟云学术

GCG100649, A Novel Cyclooxygenase-2 Inhibitor, Exhibits a Drug Disposition Profile in Healthy Volunteers Compatible With High Affinity to Carbonic Anhydrase-I/II: Preliminary Dose-Exposure Relationships to Define Clinical Development Strategies

Published:2013-07-25 Issue:4 Volume:2 Page:379-386
ISSN:2160-763X
Container-title:Clinical Pharmacology in Drug Development
language:en
Short-container-title:CPDD

Author:

Hirankarn Sarapee¹²,Barrett Jeffrey S.¹²,Alamuddin Naji²³,FitzGerald Garret A.²³,Skarke Carsten²³

Affiliation:

1. Clinical Pharmacology & Therapeutics Division; Kinetic Modeling and Simulation (KMAS) Core; The Children's Hospital of Philadelphia (CHOP); Philadelphia PA USA

2. Institute for Translational Medicine and Therapeutics (ITMAT); University of Pennsylvania; Philadelphia PA USA

3. Department of Pharmacology; University of Pennsylvania Perelman School of Medicine; Philadelphia PA USA

Funder

National Center for Research Resources

Publisher

Wiley

Subject

Pharmacology (medical),Pharmaceutical Science

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1002/cpdd.47/fullpdf

Reference24 articles.

1. Emotion recollected in tranquility: lessons learned from the COX-2 saga;Grosser;Annu Rev Med.,2010